Humanized antibodies with anti-tumor activity

US8901279B2 · kind B2 · utility

Assignee

• TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · AU

Inventors

• Adam Clarke · Chatswood, AU
• Anthony G. Doyle · Chatswood, AU
• Philip Anthony Jennings · Chatswood, AU
• Norbert Kienzle · Parramatta, AU
• Matthew Pollard · Chatswood, AU

Key dates

• Filing date: May 21, 2013
• Grant date: Dec 2, 2014
• Expiry date: May 21, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/734
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.